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Abstract
A 67-year-old Han Chinese man had been suffering from Parkinson’s disease 
(PD) for 3 years. He received slow-release Madopar 250 mg and Madopar 
375 mg per day for his PD. He suffered an L3 compression fracture in an 
accident and was hospitalized for surgery because of severe back pain. 
He was referred to a psychiatrist because of severe depression. Duloxetine 
(30 mg twice per day, without titration) was prescribed for both antide-
pressant and analgesic effects. This regimen was continued for 7 months 
with no deterioration in cognitive function, and no worsening of PD was 
observed in his monthly follow-up. Duloxetine, which is a serotonin and 
noradrenaline reuptake inhibitor, may have the same antidepressant 
effect as tricyclic antidepressants but has fewer side effects for PD patients. 
[Tzu Chi Med J 2010;22(1):68–69]
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1. Introduction
Approximately 30–40% of patients with Parkinson’s 
disease (PD) suffer from depression but only 20–25% 
of those patients receive antidepressants. In addition 
to the emotional distress, the occurrence of depres-
sion in PD has been associated with a rapid decline 
in motor symptoms, cognitive decline, and the devel-
opment of dementia, which reduces the quality of life. 
However, antiparkinsonian medications have only lim-
ited antidepressant efficacy [1].
In 2006, a subcommittee of the American Academy 
of Neurology suggested using amitriptyline to treat 
depression in PD [2]. In clinical practice, however, 
tricyclic antidepressants are not very useful in PD be-
cause of their significant side effects [3].
Duloxetine (Lilly, Indianapolis, IN, USA) is a selective 
serotonin and norepinephrine reuptake inhibitor. It is 
relatively balanced in its affinity for both serotonin 
and norepinephrine reuptake inhibition [4] and is used 
for treating major depression, especially in patients 
with pain and urinary incontinence [5].
We report the use of duloxetine, a dual-action anti-
depressant, to treat a major depressive episode in a 
patient with PD, without significant adverse effects.
2. Case report
A 67-year-old married Han Chinese male patient from 
Taiwan had been a victim of PD for 3 years. He also 
had a history of diabetes mellitus, hypertension, and 
benign prostate hypertrophy. He received Madopar 
HBS 250 mg (levodopa 200 mg, benserazide 50 mg, 
controlled-release) and Madopar 375 mg (levodopa 
100 mg, benserazide 25 mg, immediate release) per 
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day for his PD. Although he had no psychiatric illness 
before PD, he suffered from chronic dysphoria after 
the onset of PD. He sustained an L3 compression frac-
ture in an accident and was hospitalized for surgery 
because of severe back pain, for which he received 
nimesulide 100 mg twice per day. Psychiatric exami-
nation revealed that his depressive symptoms met the 
criteria of major depression according to the Diagnostic 
and Statistical Manual of Mental Disorders, Fourth 
Edition. His Montgomery-Asberg Depression Rating 
Scale (MADRS) score was 30 and the Clinical Global 
Impression-Severity (CGI-S) scale score was 6. Dul-
oxetine (30 mg twice per day, without titration) was 
prescribed for both its antidepressant and analgesic 
effects. After surgery, his back pain improved signifi-
cantly. Two weeks after the initiation of duloxetine, his 
MADRS score was 18 and the CGI-S score had im-
proved to 3. Duloxetine was continued because the 
patient and his family were satisfied with the marked 
mood improvement. Two months after the initiation of 
duloxetine, his MADRS score was 10 and the CGI-S 
score had improved to 2. This regimen continued for 
7 months with no deterioration in cognitive function, 
and no worsening of PD was observed in his monthly 
follow-up. The dosage of Madopar HBS and Madopar 
remained the same over the entire 7 months.
3. Discussion
We successfully prescribed duloxetine for our patient 
to treat a major depressive episode in PD, without sig-
nificant adverse effects. We did not follow the American 
Academy of Neurology advice to prescribe amitripty-
line, because in previous tricyclic antidepressant and 
selective serotonin reuptake inhibitor randomized 
controlled trials, high dropout rates were related to 
significant side effects, including somatic complaints, 
confusion, and visual hallucinations [6]. These symp-
toms did not occur in our case.
Discrepant severity scores as measured by the CGI 
and MADRS scales in the treatment period were noted. 
Severity scores evaluated by CGI were consistently 
higher than when evaluated by MADRS. This is unsur-
prising because the CGI score reflects discomfort in-
duced by L3 compression fracture, PD and depression, 
while the MADRS does not clearly reflect somatic 
symptoms. Duloxetine has proven to be efficacious 
in treating depressed patients with pain symptoms [7]. 
However, in our patient, we attributed the analgesic 
effect mainly to surgical treatment.
Current clinical evidence suggests that newer dual-
action antidepressants (duloxetine, venlafaxine, mil-
nacipran) may offer improved efficacy, faster onset of 
action compared with selective serotonin reuptake 
inhibitors, and an improved side effect profile than 
tricyclic antidepressants [8]. In a matched group study, 
depressed PD patients had higher rates of newer non-
selective serotonin reuptake inhibitor use (20.6% vs. 
19.2%, p < 0.05) and lower rates of tricyclic antide-
pressant use (7.4% vs. 8.9%, p < 0.001) than non-
depressed PD patients [3].
In conclusion, duloxetine, which is a serotonin and 
noradrenaline reuptake inhibitor, may have the same 
antidepressant effect for PD patients as tricyclic anti-
depressants but with fewer side effects. It should be 
noted, however, that possible adverse effects of du-
loxetine include nausea, dry mouth, fatigue, and de-
creased appetite [9]. On the other hand, tremors might 
be a symptom of deteriorating PD or excessive no-
radrenaline, and therefore, more evidence for differ-
ential diagnosis is required [10]. These adverse events 
could be monitored by careful inquiry and physical 
examination.
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